Mark H. O’Hara, MD, assistant professor of medicine, Hospital of the University of Pennsylvania, discusses the rationale for evaluating APX005M in combination with chemotherapy and nivolumab (Opdivo) in pancreatic cancer.
Mark H. O'Hara, MD
Advertisement
Articles by Mark H. O'Hara, MD
Advertisement
Latest Updated Articles
Dr. O'Hara on the Rationale for APX005M in Combination With Chemotherapy and Nivolumab in Pancreatic CancerPublished: April 26th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5